Loading your page…
Marketing-authorisation holder
3 medicines in 1 country, as authorisation holder and manufacturer.
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
Every medicine in the registers under its name, current ones first.
3 medicines
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| ERYTHROMYCIN250mg | 500mg · Tablet | Erythromycin | United States | Marketed | 1972 |
| RANOLAZINE1000mg | 1gm | 500mg · Tablet, extended release | Ranolazine | United States | Marketed | 2013 |
| VERAPAMIL HYDROCHLORIDE120mg | 180mg | 240mg · Tablet, extended release | Verapamil | United States | Marketed | 1992 |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| United States | 3 | 3 | 0 | CompaniesAll medicines |
Also in the registers of Brazil
The active substances in most of its medicines.
How the registers spell it, normalised: legal forms, accents and capitals removed.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Source: U.S. FDA, Drugs@FDA / openFDA. FDA does not endorse this site.
Licence: Public domain (U.S. Government work)
Anvisa, official medicine/API manufacturer factual export, HTTP source version Fri, 09 Oct 2026 08:21:54 GMT, acquired 2026-10-09; exact unmodified native identifiers and fields preserved.
Licence: Brazil federal factual open-data reuse; Decreto 8777/2016 consolidated article 4 and third-party exceptions
Report an error or request removalCorrections from the company itself are welcome.
